Literature DB >> 19929457

Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice.

Erika Deak1, Brigitte Rüster, Lisa Keller, Klaus Eckert, Iduna Fichtner, Erhard Seifried, Reinhard Henschler.   

Abstract

Intravenous (i.v.) transplantation and subsequent homing of Mesenchymal Stromal Cells (MSC) may be adversely influenced by their relatively high adhesion capacity and their tendency to aggregate, leading to clogging of capillaries especially in the lungs. We evaluated the ability of murine MSC suspended in EDTA or heparin in buffered saline solution on their spontaneous adhesion to endothelial cells in vitro, under shear stress and their in vivo tolerability after i.v. injection. We show that suspension of MSC in heparin was highly beneficial, avoiding clinical symptoms in 95% of mice, whereas application of MSC suspended in PBS/EDTA or control buffer caused severe pulmonary reactions and partly, death. In vitro studies using parallel plate flow chambers revealed increased adhesion of MSC suspended in PBS/EDTA to endothelial cells compared with MSC in PBS/heparin. These data provide a means to predict and to interfere with toxicity of i.v. transplanted MSC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19929457     DOI: 10.3109/14653240903401840

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  13 in total

1.  Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue.

Authors:  Erja Kerkelä; Tanja Hakkarainen; Tuomas Mäkelä; Mari Raki; Oleg Kambur; Lotta Kilpinen; Janne Nikkilä; Siri Lehtonen; Ilja Ritamo; Roni Pernu; Mika Pietilä; Reijo Takalo; Tatu Juvonen; Kim Bergström; Eija Kalso; Leena Valmu; Saara Laitinen; Petri Lehenkari; Johanna Nystedt
Journal:  Stem Cells Transl Med       Date:  2013-06-03       Impact factor: 6.940

2.  Optimization of mesenchymal stem cells (MSCs) delivery dose and route in mice with acute liver injury by bioluminescence imaging.

Authors:  Zhengran Li; Xiaojun Hu; Junjie Mao; Xuelian Liu; Lina Zhang; Jingjing Liu; Dan Li; Hong Shan
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

Review 3.  Humanized Mouse Models for Evaluation of PSC Immunogenicity.

Authors:  Jack Hermsen; Matthew E Brown
Journal:  Curr Protoc Stem Cell Biol       Date:  2020-09

Review 4.  Data against a Common Assumption: Xenogeneic Mouse Models Can Be Used to Assay Suppression of Immunity by Human MSCs.

Authors:  Darwin J Prockop; Joo Youn Oh; Ryang Hwa Lee
Journal:  Mol Ther       Date:  2017-06-22       Impact factor: 11.454

5.  Translating research into clinical scale manufacturing of mesenchymal stromal cells.

Authors:  Karen Bieback; Sven Kinzebach; Marianna Karagianni
Journal:  Stem Cells Int       Date:  2011-01-20       Impact factor: 5.443

6.  Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells.

Authors:  Jeong Chan Ra; Sung Keun Kang; Il Seob Shin; Hyeong Geun Park; Sang Aun Joo; Jeong Geun Kim; Byeong-Cheol Kang; Yong Soon Lee; Ken Nakama; Min Piao; Bertram Sohl; Andras Kurtz
Journal:  J Transl Med       Date:  2011-10-21       Impact factor: 5.531

7.  Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?

Authors:  Guido Moll; Annika Hult; Lena von Bahr; Jessica J Alm; Nina Heldring; Osama A Hamad; Lillemor Stenbeck-Funke; Stella Larsson; Yuji Teramura; Helene Roelofs; Bo Nilsson; Willem E Fibbe; Martin L Olsson; Katarina Le Blanc
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

Review 8.  Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells.

Authors:  Johannes Leibacher; Reinhard Henschler
Journal:  Stem Cell Res Ther       Date:  2016-01-11       Impact factor: 6.832

9.  Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health.

Authors:  Claire Fabian; Yahaira Naaldijk; Christiane Leovsky; Adiv A Johnson; Lukas Rudolph; Carsten Jaeger; Katrin Arnold; Alexandra Stolzing
Journal:  Stem Cell Res Ther       Date:  2017-04-18       Impact factor: 6.832

10.  Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies.

Authors:  Jessica M Quimby; Tracy L Webb; Lauren M Habenicht; Steven W Dow
Journal:  Stem Cell Res Ther       Date:  2013-04-30       Impact factor: 8.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.